FP USA Will Leverage Global Operations Footprint

FOSUN PHARMA USA INC.

R&D Innovation

- 4 core technology platforms
- 7 core therapeutic areas
- 3400+ R&D staff
- 70+ in-progress innovative drug and biosimilar projects (by indication)

Manufacturing System

- Vertical integration of the chemical API and formulation, clustering to the advantageous manufacturing capacity
- Commercialized production capacity of 48,000L for biologics
- 100+ official inspections
- 600+ batches of official sampling
- 9 manufacturing lines have passed GMP certification of US FDA, EU and other markets

Commercialization System

- Professionalization, branding, digitalization, compliance
- ~5,000 commercialization staffs in China
- ~1,000 overseas commercialization staffs
- Continuous optimization of marketing compliance management system

FP USA Will Leverage Global Operations Footprint

FOSUN PHARMA USA INC.

Integrated Formulation

Xuzhou Industrial Park

Yao Pharma

Gland Pharma

APIs

Xingnuo

Dongting

Changshou

Biologics

Henlius

Adgenvax

Small Molecule API **Small Molecule Formulation** **Biologics**

International Standard Manufacturing

- 10+ production lines for API and formulation of Yao Pharma, Wanbang and Guilin Pharma received GMP certifications from the U.S., Europe, etc.
- Integrating manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou Industrial Park Formulation Plant and of API facilities in Changsha, Xuzhou and Chongqing
- Commercialization capacity of Henlius is 48,000L now and will reach 144,000L in 2026; Xuhui plant has passed dual GMP certification in both China and Europe
- Fosun Adgenvax received Drug Manufacturing License and the Drug Operation Licence, supporting its subsequent commercialization of in-line vaccine products
- Constructing the Côte d'Ivoire Industrial Park in order to achieve localizing products manufacturing and distributing in Africa
- Gland Pharma received GMP certifications from the U.S., EU, Japan, Australia, etc.; Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO

Plant	Date	Product	Progress
Henlius Songjiang (1st Plant)	Aug '23	Trastuzumab injection (HER2)	Accept FDA Pre-approval test
Henlius Xuhui	Oct '23	Serplulimab Injection (PD-1)	Passed Indonesian BPOM GMP inspection
Henlius Xuhui	Oct '23	Serplulimab Injection (PD-1), Trastuzumab injection (HER2)	Passed Brazilian ANVISA inspection
Henlius Xuhui	Nov '23	Rituximab injection (CD20) DS&DP	Passed Colombian INVIMA inspection
Henlius Xuhui & Songjiang(1st Plant)	Dec '23	Serplulimab Injection (PD-1)	Obtained EU GMP certificates
Guilin Pharma	Oct '23	Sertraline Hydrochloride Tablets and Compound Sulfamethoxazole Tablets	Passed FDA Pre-Approval Inspection